fidaxomicin   Click here for help

GtoPdb Ligand ID: 10909

Synonyms: Dificid® | Dificlir® | lipiarmycin | OPT-80 | PAR-101 | tiacumicin B
Approved drug PDB Ligand
fidaxomicin is an approved drug (EMA & FDA (2011))
Compound class: Synthetic organic
Comment: Fidaxomicin is a narrow-spectrum, semisynthetic, macrolide antibacterial. It was isolated from the hamdenensis subspecies of actinomycete Dactylosporangium aurantiacum.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 16
Hydrogen bond donors 7
Rotatable bonds 15
Topological polar surface area 266.66
Molecular weight 1056.43
XLogP 5.76
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CO[C@@H]1[C@H](OC/C/2=C\C=C\C[C@H](O)/C(=C/[C@H](CC)[C@H](/C(=C/C(=C/C[C@H](OC2=O)[C@H](O)C)/C)/C)O[C@@H]2OC(C)(C)[C@H]([C@@H]([C@@H]2O)O)OC(=O)C(C)C)/C)O[C@@H]([C@H]([C@@H]1O)OC(=O)c1c(O)c(Cl)c(c(c1CC)Cl)O)C
Isomeric SMILES CO[C@@H]1[C@H](OC/C/2=C\C=C\C[C@H](O)/C(=C/[C@H](CC)[C@H](/C(=C/C(=C/C[C@H](OC2=O)[C@H](O)C)/C)/C)O[C@@H]2OC(C)(C)[C@H]([C@@H]([C@@H]2O)O)OC(=O)C(C)C)/C)O[C@@H]([C@H]([C@@H]1O)OC(=O)c1c(O)c(Cl)c(c(c1CC)Cl)O)C
InChI InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1
InChI Key ZVGNESXIJDCBKN-UUEYKCAUSA-N
No information available.
Summary of Clinical Use Click here for help
Orally administered fidaxomicin is minimally absorbed into the systemic circulation, and principally acts locally in the gastrointestinal tract. It is used to treat Clostridium difficile-associated diarrhea (CDAD). The MIC90 for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection prior to fidaxomicin's approval. As of January 2020, fidaxomicin has FDA approval for use in children aged ≥6 months for CDAD.
External links Click here for help